Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...
Bernstein downgraded Genmab (GMAB) to Underperform from Market Perform with a price target of DKK 1,000, down from DKK 1,580. The share price ...
Core & Main downgraded due to uncertain macro conditions and slow growth. Read why CNM stock is downgraded to hold due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback